| | | The 2022 HNCA Survivorship Webinar Series Begins Next Week |
| Join HNCA and the American Head and Neck Society for our first Survivorship Webinar of 2022. Mind and Body Therapies for Head and Neck Cancer Patients and Survivors looks at holistic healing methods that bring the mental and physical aspects of the body into harmony to promote whole-body wellness. Learn the benefits of techniques such as yoga, meditation, and mindfulness. This webinar will include a 10-minute experiential segment. Attendees should have a comfortable chair with back support to best participate in the segment. Headphones are also recommended. Registration is open now! The deadline to register is January 20 at 12:00pm Eastern. |
| |  | |
|
| Coming Soon: Substance Abuse Webinar Coming in March, HNCA and AHNS will present a webinar on an important topic for cancer survivors and caregivers: Preventing, recognizing, and dealing with dependence on substances or alcohol. Details are being finalized, and more information will be available soon! |
|
|
| |  | HNCA is hosting its 24th annual Oral, Head and Neck Cancer Awareness Week® (OHANCAW®) April 3 - 9, 2022. For more than two decades, HNCA has worked with partners around the world to raise awareness of head and neck cancer and promote early detection. Registration is now open for medical and dental partners planning to host a screening event during Awareness Week. We understand many sites may have challenges with hosting a screening event due to COVID-19 restrictions, so we are encouraging sites to: - Work with their respective institutions’ public health teams to determine the appropriate timing and venue to optimize the safety of your head and neck cancer screening event.
- Plan for a screening in the latter part of 2022 when conditions are better. HNCA is pleased to offer the same educational and promotional support—free of charge—for all screenings offered in 2022.
- Share this email with dental offices in your local community, who are currently seeing patients, and can serve as the first line of defense in detecting head and neck cancer.
Our partners can also get involved in other ways, such as participating in our online awareness-raising campaign, hosting a virtual educational activity, or sharing OHANCAW print and digital materials in their waiting and exam rooms. More information about activities for Oral, Head and Neck Cancer Awareness Week will be available soon! |
| | | This program is generously supported by grants from |
| | | | |
|
| | The COVID-19 pandemic has caused delays, postponements, and cancellations resulting in dramatic drops in HPV immunizations and cancer screenings worldwide. This webinar series will focus on the effort needed to build back an effective, sustainable, and inclusive pathway to recovery so as not to undo the progress we have made thus far. North American HPV Awareness Week, January 24-28, hosted by the American Women's Medical Association, Global Initiative Against HPV & Cervical Cancer, and IU National Center of Excellence in Women’s Health. Thursday's session focuses on HPV-related head and neck cancer. Join the free webinar, HPV Head and Neck Cancers: What you Don’t Know CAN Hurt You with moderator Cecelia E. Schmalbach, MD, MSc, FACS on Thursday, Jan. 27, 2022, from 12:00 - 1:00 pm EST. |
| |
|
| | The Future of Head and Neck Cancer: Emerging Treatments, Clinical Trials, and Research Studies *Sponsor Content | Learn HNCA's stance on corporate support below. |
| HNCA’s work would not be possible without our sponsors and partners. Please see below to learn more about our partners and the clinical trials that are underway to help head and neck cancer patients. For more information about clinical trials and where to find trials that might apply to you or a loved one, visit our Clinical Trial Finder or click on any of the trial opportunities below. |
|  | |  |  |  | |  | |  | Rakuten Medical’s global Phase 3 multi-center clinical trial with ASP-1929 to evaluate its efficacy and safety in patients with recurrent head and neck squamous cell carcinoma. ASP-1929 photoimmunotherapy is a combination drug and device anticancer treatment that utilizes a cetuximab monoclonal antibody conjugated to a photoactivatable dye that can be excited upon localized nonthermal 690 nm red light illumination to induce rapid cell death of target tumor cells. In the ASP-1929-301 study, enrolled patients will be randomized in a 2:1 fashion to receive either ASP-1929 photoimmunotherapy or physician’s choice standard of care (methotrexate, docetaxel, paclitaxel or cetuximab). The study is actively enrolling in 3 regions: Taiwan, Japan and the United States. ClinicalTrials.gov Identifier: NCT03769506 |
|  | *Statement on Sponsor Content and Corporate Support: The information published on this website and in our materials is intended to educate you about Oral, Head and Neck Cancer. The content is not intended to take the place of a discussion with a qualified physician who is familiar with your medical situation. It is important to remember that each individual is different, and the reasons for—and outcomes of—any treatment plan depends on the patient's individual condition. If you have questions or concerns after reading any information on this website or in our materials, you should discuss them openly and honestly with your physician. Any products and manufacturers included on this site are presented for informational purposes only and do not constitute product approval or endorsement by HNCA. The content provided by HNCA is in no way intended to be a substitute for medical consultation with a qualified professional. HNCA encourages those using its resources to be careful when evaluating medical information or products. If you are unsure about your medical condition, consult a physician. Funding from our corporate partners supports HNCA’s programs and educational initiatives, and HNCA maintains independence in its design of programs, content, and initiatives. |
|
|
| | | Thank You to our Corporate and Community Partners |
|  | | | | |
|
| | Head and Neck Cancer Alliance
PO BOX 21688 | Charleston, South Carolina 29413
866-792-4622 | info@headandneck.org |
| | Be sure to add our email address to your address book or safe senders list so our emails get to your inbox. Having trouble viewing this email? View it in your web browser |
|
|
| |
|
|
